Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 4 (2007), Issue 3 (March)

1. Unopposed estradiol therapy in postmenopausal women: results from two randomized trials.
   Obstet Gynecol, 109(3): 581-7. [Abstract] [Full-text]
2. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
   Lancet Oncol, 8(3): 219-25. [Abstract] [Full-text]
3. Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy.
   J Infect Dis, 195(7): 965-72. [Abstract] [Full-text]
4. Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer.
   Cancer Immunol Immunother, 56(5): 699-708. [Abstract] [Full-text]
5. Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human malignant glioblastoma T98G and U87MG cells.
   Cancer Immunol Immunother, 56(5): 615-25. [Abstract] [Full-text]
6. Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy.
   Cancer Immunol Immunother, 56(5): 649-58. [Abstract] [Full-text]
7. A comparison of midazolam and midazolam with remifentanil for patient-controlled sedation during operations on third molars.
   Br J Oral Maxillofac Surg, 45(3): 212-6. [Abstract] [Full-text]
8. Adverse reactions to the Bacillus Calmette-Guerin vaccine in HIV-positive infants.
   J Pediatr Surg, 42(3): 549-52. [Abstract] [Full-text]
9. Early experience with the antegrade colonic enema stopper to reduce stomal stenosis.
   J Pediatr Surg, 42(3): 522-4. [Abstract] [Full-text]
10. Successful treatment of a bowel perforation after chemotherapy for Burkitt lymphoma.
    J Pediatr Surg, 42(3): E1-3. [Abstract] [Full-text]
11. Photodynamic therapy and cancer: a brief sightseeing tour.
    Expert Opin Drug Deliv, 4(2): 131-48. [Abstract] [Full-text]
12. The microfabricated electrokinetic pump: a potential promising drug delivery technique.
    Expert Opin Drug Deliv, 4(2): 119-29. [Abstract] [Full-text]
13. Mesoporous silicon: a platform for the delivery of therapeutics.
    Expert Opin Drug Deliv, 4(2): 101-10. [Abstract] [Full-text]
14. Liposome-based drug delivery to alveolar macrophages.
    Expert Opin Drug Deliv, 4(2): 95-9. [Abstract] [Full-text]
15. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients.
    Expert Opin Drug Deliv, 4(2): 91-4. [Abstract] [Full-text]
16. Successful treatment of advanced gastric cancer by surgical resection following combination chemotherapy with oral S-1 and biweekly paclitaxel.
    Gastric Cancer, 10(1): 58-62. [Abstract] [Full-text]
17. Anesthetic related advances with cyclodextrins.
    ScientificWorldJournal, 7: 364-71. [Abstract] [Full-text]
18. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
    Int J Radiat Oncol Biol Phys, 67(4): 995-1001. [Abstract] [Full-text]
19. Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices.
    Life Sci, 80(14): 1327-34. [Abstract] [Full-text]
20. A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
    Int J Radiat Oncol Biol Phys, 67(4): 1002-7. [Abstract] [Full-text]
21. Characterization of prototype self-nanoemulsifying formulations of lipophilic compounds.
    J Pharm Sci, 96(4): 876-92. [Abstract] [Full-text]
22. Perfectionism and eating disorders: current status and future directions.
    Clin Psychol Rev, 27(3): 384-405. [Abstract] [Full-text]
23. Investigation of drug-porous adsorbent interactions in drug mixtures with selected porous adsorbents.
    J Pharm Sci, 96(4): 851-63. [Abstract] [Full-text]
24. Interaction of cationic vesicle with ribonucleotides (AMP, ADP, and ATP) and physicochemical characterization of DODAB/ribonucleotides complexes.
    Biophys Chem, 127(1): 19-27. [Abstract] [Full-text]
25. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications.
    J Pharm Sci, 96(4): 729-46. [Abstract] [Full-text]
26. Interpreting properties of microbicide drug delivery gels: analyzing deployment kinetics due to squeezing.
    J Pharm Sci, 96(4): 835-50. [Abstract] [Full-text]
27. Improving the loading and release of NSAIDs from pHEMA hydrogels by copolymerization with functionalized monomers.
    J Pharm Sci, 96(4): 802-13. [Abstract] [Full-text]
28. Addressing medication errors--The role of undergraduate nurse education.
    Nurse Educ Today, 27(3): 219-24. [Abstract] [Full-text]
29. Antitumor effects and blood flow dynamics after photodynamic therapy using benzoporphyrin derivative monoacid ring A in KLN205 and LM8 mouse tumor models.
    Cancer Lett, 248(1): 47-57. [Abstract] [Full-text]
30. The pharmacogenetics research network: from SNP discovery to clinical drug response.
    Clin Pharmacol Ther, 81(3): 328-45. [Abstract] [Full-text]
31. Enhancing race-based prescribing precision with pharmacogenomics.
    Clin Pharmacol Ther, 81(3): 323-5. [Abstract] [Full-text]
32. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis.
    Neurology, 68(10): 737-42. [Abstract] [Full-text]
33. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy.
    Gut, 56(3): 390-5. [Abstract] [Full-text]
34. Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs.
    J Control Release, 118(2): 196-203. [Abstract] [Full-text]
35. Controlled-release of epidermal growth factor from cationized gelatin hydrogel enhances corneal epithelial wound healing.
    J Control Release, 118(2): 169-76. [Abstract] [Full-text]
36. Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.
    Cancer Treat Rev, 33(2): 101-37. [Abstract] [Full-text]
37. Mechanisms controlling protein release from lipidic implants: effects of PEG addition.
    J Control Release, 118(2): 161-8. [Abstract] [Full-text]
38. Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium.
    J Control Release, 118(2): 235-44. [Abstract] [Full-text]
39. Applications of carrier erythrocytes in delivery of biopharmaceuticals.
    J Control Release, 118(2): 145-60. [Abstract] [Full-text]
40. Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterisation studies.
    J Control Release, 118(2): 225-34. [Abstract] [Full-text]
41. FcgammaR: The key to optimize therapeutic antibodies?
    Crit Rev Oncol Hematol, 62(1): 26-33. [Abstract] [Full-text]
42. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors.
    J Control Release, 118(2): 216-24. [Abstract] [Full-text]
43. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Cancer Lett, 248(2): 165-74. [Abstract] [Full-text]
44. Major and minor ECG abnormalities in asymptomatic women and risk of cardiovascular events and mortality.
    JAMA, 297(9): 978-85. [Abstract] [Full-text]
45. Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy?
    Clin Infect Dis, 44(7): 996-1000. [Abstract] [Full-text]
46. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
    Clin Infect Dis, 44(7): 988-95. [Abstract] [Full-text]
47. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor.
    Clin Infect Dis, 44(7): 921-7. [Abstract] [Full-text]
48. Release of gentamicin from bone regenerative materials: an in vitro study.
    J Biomed Mater Res B Appl Biomater, 81(1): 23-9. [Abstract] [Full-text]
49. Degradation and drug release property of star poly(epsilon-caprolactone)s with dendritic cores.
    J Biomed Mater Res B Appl Biomater, 81(1): 40-9. [Abstract] [Full-text]
50. Radiation synthesis of poly(ethylene glycol)/acrylic acid hydrogel as carrier for site specific drug delivery.
    J Biomed Mater Res B Appl Biomater, 81(1): 168-74. [Abstract] [Full-text]
51. Development and characterization of novel photosensitizer : scFv conjugates for use in photodynamic therapy of cancer.
    Immunology, 120(4): 512-7. [Abstract] [Full-text]
52. Endodermal sinus tumor of the vagina.
    Pediatr Blood Cancer, 48(5): 577-8. [Abstract] [Full-text]
53. Reinduction of relapsed acute promyelocytic leukemia with ATRA and low dose antimetabolite-based chemotherapy.
    Pediatr Blood Cancer, 48(5): 582-5. [Abstract] [Full-text]
54. Meta-analysis comparing CT colonography, air contrast barium enema, and colonoscopy.
    Am J Med, 120(3): 203-210.e4. [Abstract] [Full-text]
55. Comparative benefit of two thermal spring waters after photodynamic therapy procedure.
    J Cosmet Dermatol, 6(1): 31-5. [Abstract] [Full-text]
56. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
    Anticancer Drugs, 18(4): 487-91. [Abstract] [Full-text]
57. A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer.
    Anticancer Drugs, 18(4): 471-6. [Abstract] [Full-text]
58. Prescription rheumatology practices among Mexican specialists.
    Arch Med Res, 38(3): 354-9. [Abstract] [Full-text]
59. Oestrogen replacement therapy reduces total plasma homocysteine and enhances genomic DNA methylation in postmenopausal women.
    Br J Nutr, 97(4): 617-21. [Abstract] [Full-text]
60. Nanohybrids for controlled antibiotic release in topical applications.
    Int J Antimicrob Agents, 29(4): 417-23. [Abstract] [Full-text]
61. Fatal ischemic bowel necrosis possibly due to docetaxel and cisplatin in a patient with non-small cell lung cancer.
    Lung Cancer, 56(1): 143-4. [Abstract] [Full-text]
62. Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas.
    J Dermatol Sci, 46(1): 11-20. [Abstract] [Full-text]
63. A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma.
    Lung Cancer, 56(1): 89-95. [Abstract] [Full-text]
64. Factors associated with medication hassles experienced by family caregivers of older adults.
    Patient Educ Couns, 66(1): 51-7. [Abstract] [Full-text]
65. Dissecting drug and vehicle metabolic effects in rats by a metabonomic approach.
    J Biochem Biophys Methods, 70(3): 355-61. [Abstract] [Full-text]
66. Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke.
    Neurology, 68(11): 842-8. [Abstract] [Full-text]
67. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.
    Arch Ophthalmol, 125(3): 309-17. [Abstract] [Full-text]
68. Drug therapy in dental practice: general principles. Part 2 - pharmacodynamic considerations.
    Anesth Prog, 54(1): 19-23; quiz 24-5. [Abstract] [Full-text]
69. Encapsulation and release of a hydrophobic drug from hydroxyapatite coated liposomes.
    Biomaterials, 28(16): 2687-94. [Abstract] [Full-text]
70. The effect of the controlled release of basic fibroblast growth factor from ionic gelatin-based hydrogels on angiogenesis in a murine critical limb ischemic model.
    Biomaterials, 28(16): 2646-54. [Abstract] [Full-text]
71. Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo.
    Biomaterials, 28(16): 2655-66. [Abstract] [Full-text]
72. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker.
    J Acquir Immune Defic Syndr, 44(4): 463-9. [Abstract] [Full-text]
73. Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study.
    J Acquir Immune Defic Syndr, 44(4): 451-5. [Abstract] [Full-text]
74. Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).
    J Acquir Immune Defic Syndr, 44(4): 395-400. [Abstract] [Full-text]
75. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
    Curr Med Res Opin, 23(3): 533-43. [Abstract] [Full-text]
76. Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration.
    Curr Med Res Opin, 23(3): 477-87. [Abstract] [Full-text]
77. Local delivery system of cytotoxic agents to tumors by focused sonoporation.
    Cancer Gene Ther, 14(4): 354-63. [Abstract] [Full-text]
78. Targeting AMPA receptor gating processes with allosteric modulators and mutations.
    Biophys J, 92(7): 2392-402. [Abstract] [Full-text]
79. Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.
    J Neurooncol, 82(2): 177-81. [Abstract] [Full-text]
80. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries.
    Clin Infect Dis, 44(8): 1091-5. [Abstract] [Full-text]
81. Increasing survival of ischemic tissue by targeting CD47.
    Circ Res, 100(5): 712-20. [Abstract] [Full-text]
82. A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo.
    J Invest Dermatol, 127(4): 881-6. [Abstract] [Full-text]
83. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    J Clin Oncol, 25(9): 1114-20. [Abstract] [Full-text]
84. Intravenous repeated-dose toxicity study of ZnPcS2P2-based-photodynamic therapy in beagle dogs.
    Regul Toxicol Pharmacol, 47(3): 221-31. [Abstract] [Full-text]
85. 5-Aminolevulinic acid-based photodynamic therapy suppressed survival factors and activated proteases for apoptosis in human glioblastoma U87MG cells.
    Neurosci Lett, 415(3): 242-7. [Abstract] [Full-text]
86. Psyllium as therapeutic and drug delivery agent.
    Int J Pharm, 334(1): 1-14. [Abstract] [Full-text]
87. Hydrogen-bonded interpolymer complexes as materials for pharmaceutical applications.
    Int J Pharm, 334(1): 15-26. [Abstract] [Full-text]
88. Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres.
    Int J Pharm, 334(1): 137-48. [Abstract] [Full-text]
89. Use of hormone replacement therapy (HRT) among women aged 45-64 years in the German EPIC-cohorts.
    Maturitas, 56(4): 436-46. [Abstract] [Full-text]
90. Spanish post-menopausal women's viewpoints on hormone therapy.
    Maturitas, 56(4): 420-8. [Abstract] [Full-text]
91. Ventricular endocrine and mechanical function following thrombolysis for acute myocardial infarction.
    Int J Cardiol, 117(1): 51-8. [Abstract] [Full-text]
92. Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid.
    Int J Pharm, 334(1): 179-89. [Abstract] [Full-text]
93. Ethanolic extracts of black cohosh (Actaea racemosa) inhibit growth and oestradiol synthesis from oestrone sulphate in breast cancer cells.
    Maturitas, 56(4): 359-67. [Abstract] [Full-text]
94. Evaluation of bioadhesive potential and intestinal transport of pegylated poly(anhydride) nanoparticles.
    Int J Pharm, 334(1): 156-65. [Abstract] [Full-text]
95. ABA and BAB type triblock copolymers of PEG and PLA: a comparative study of drug release properties and "stealth" particle characteristics.
    Int J Pharm, 334(1): 48-55. [Abstract] [Full-text]
96. Influence of carrier on the performance of dry powder inhalers.
    Int J Pharm, 334(1): 85-91. [Abstract] [Full-text]
97. Alginate microspheres of isoniazid for oral sustained drug delivery.
    Int J Pharm, 334(1): 71-7. [Abstract] [Full-text]
98. Sustained antibacterial effect of a hand rub gel incorporating chlorhexdine-loaded nanocapsules (Nanochlorex).
    Int J Pharm, 334(1): 166-72. [Abstract] [Full-text]
99. Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.
    Maturitas, 56(4): 343-9. [Abstract] [Full-text]
100. Numerical analysis of forced injection of enzyme during thrombolysis.
     Comput Biol Med, 37(5): 655-62. [Abstract] [Full-text]
101. Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis.
     J Cyst Fibros, 6(2): 137-43. [Abstract] [Full-text]
102. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
     BMC Infect Dis, 7: 14. [Abstract] [Full-text]
103. N-cadherin as a therapeutic target in cancer.
     Expert Opin Investig Drugs, 16(4): 451-65. [Abstract] [Full-text]
104. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.
     Pharm Res, 24(4): 748-57. [Abstract] [Full-text]
105. Isothermal crystallization of Imwitor 742 from supercooled liquid state.
     Pharm Res, 24(4): 738-47. [Abstract] [Full-text]
106. Synthesis and coating of cobalt ferrite nanoparticles: a first step toward the obtainment of new magnetic nanocarriers.
     Langmuir, 23(7): 4026-8. [Abstract] [Full-text]
107. Differentiation restricted endocytosis of cell penetrating peptides in MDCK cells corresponds with activities of Rho-GTPases.
     Pharm Res, 24(4): 628-42. [Abstract] [Full-text]
108. Spray-drying nanocapsules in presence of colloidal silica as drying auxiliary agent: formulation and process variables optimization using experimental designs.
     Pharm Res, 24(4): 650-61. [Abstract] [Full-text]
109. Surfactant-polymer nanoparticles: a novel platform for sustained and enhanced cellular delivery of water-soluble molecules.
     Pharm Res, 24(4): 803-10. [Abstract] [Full-text]
110. Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer.
     Trends Biotechnol, 25(4): 145-52. [Abstract] [Full-text]
111. Visualizing the structure of triglyceride nanoparticles in different crystal modifications.
     Langmuir, 23(7): 4005-11. [Abstract] [Full-text]
112. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
     Cancer Chemother Pharmacol, 59(6): 771-9. [Abstract] [Full-text]
113. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
     Cancer Chemother Pharmacol, 59(6): 789-94. [Abstract] [Full-text]
114. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
     Cancer Chemother Pharmacol, 59(6): 703-9. [Abstract] [Full-text]
115. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
     Cancer Chemother Pharmacol, 59(6): 725-32. [Abstract] [Full-text]
116. Accuracy and performance of a commercially available Dosing Aid.
     Br J Ophthalmol, 91(4): 497-9. [Abstract] [Full-text]
117. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
     J Natl Cancer Inst, 99(6): 442-50. [Abstract] [Full-text]
118. Photodynamic therapy: update 2006. Part 2: Clinical results.
     J Eur Acad Dermatol Venereol, 21(4): 439-51. [Abstract] [Full-text]
119. Relationship between subcellular localisation of Foscan and caspase activation in photosensitised MCF-7 cells.
     Br J Cancer, 96(6): 944-51. [Abstract] [Full-text]
120. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
     Br J Cancer, 96(6): 912-7. [Abstract] [Full-text]
121. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.
     Br J Cancer, 96(6): 896-902. [Abstract] [Full-text]
122. World Health Organization program for the selection and use of essential medicines.
     Clin Pharmacol Ther, 81(4): 603-6. [Abstract] [Full-text]
123. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment.
     Expert Opin Pharmacother, 8(5): 679-88. [Abstract] [Full-text]
124. A comparison of laser-assisted drug delivery at two output energies for enhancing the delivery of topically applied LMX-4 cream prior to venipuncture.
     Anesth Analg, 104(4): 847-9. [Abstract] [Full-text]
125. Practice ordering guidance for neonatal parenteral nutrition.
     J Perinatol, 27(4): 220-4. [Abstract] [Full-text]
126. Novel therapeutic agents in acute myeloid leukemia.
     Exp Hematol, 35(4): 163-6. [Abstract] [Full-text]
127. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
     Exp Hematol, 35(4): 155-62. [Abstract] [Full-text]
128. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
     Exp Hematol, 35(4): 534-40. [Abstract] [Full-text]
129. Can Australian nurses safely assess for thrombolysis on EKG criteria?
     J Emerg Nurs, 33(2): 102-9. [Abstract] [Full-text]
130. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer.
     Ann Thorac Surg, 83(4): 1245-9; discussion 1250. [Abstract] [Full-text]
131. Resource consumption in the infection control management of pertussis exposure among healthcare workers in pediatrics.
     Infect Control Hosp Epidemiol, 28(4): 412-7. [Abstract] [Full-text]
132. The evolving role of health educators in advancing patient safety: forging partnerships and leading change.
     Health Promot Pract, 8(2): 119-27. [Abstract] [Full-text]
133. Comparison of lactated Ringer's solution and 0.9% saline in the treatment of rhabdomyolysis induced by doxylamine intoxication.
     Emerg Med J, 24(4): 276-80. [Abstract] [Full-text]
134. Safe and effective outpatient treatment of adults with chemotherapy-induced neutropenic fever.
     Am J Health Syst Pharm, 64(7): 717-22. [Abstract] [Full-text]
135. Hormonal therapy and depression: are we overlooking an important therapeutic alternative?
     J Psychosom Res, 62(4): 473-85. [Abstract] [Full-text]
136. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials.
     Am Heart J, 153(4): 579-86. [Abstract] [Full-text]
137. Chemotherapy for metastatic or unresectable bladder cancer.
     Semin Oncol, 34(2): 135-44. [Abstract] [Full-text]
138. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation.
     Semin Oncol, 34(2): 122-8. [Abstract] [Full-text]
139. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
     Biol Blood Marrow Transplant, 13(4): 454-62. [Abstract] [Full-text]
140. Deubiquitinating enzymes as novel anticancer targets.
     Future Oncol, 3(2): 191-9. [Abstract] [Full-text]
141. Role of bevacizumab for the treatment of non-small-cell lung cancer.
     Future Oncol, 3(2): 131-9. [Abstract] [Full-text]
142. Clinical and economic implications of new strategies for heart failure management in the managed care setting.
     Pharmacotherapy, 27(4): 29S-32S. [Abstract] [Full-text]
143. Underutilization of evidence-based therapies in heart failure: the pharmacist's role.
     Pharmacotherapy, 27(4): 18S-28S. [Abstract] [Full-text]
144. FK-506 extended the therapeutic time window for thrombolysis without increasing the risk of hemorrhagic transformation in an embolic rat stroke model.
     Brain Res, 1143: 221-7. [Abstract] [Full-text]
145. N-phthaloylchitosan-g-mPEG design for all-trans retinoic acid-loaded polymeric micelles.
     Eur J Pharm Sci, 30(5): 424-31. [Abstract] [Full-text]
146. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer.
     Qual Life Res, 16(4): 571-5. [Abstract] [Full-text]
147. Advanced malignant rhabdoid tumor of the ovary effectively responding to chemotherapy: a case report and review of the literature.
     Gynecol Oncol, 105(1): 261-5. [Abstract] [Full-text]
148. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells.
     Eur J Pharm Sci, 30(5): 380-91. [Abstract] [Full-text]
149. Long-term follow-up after neoadjuvant chemotherapy for high-risk cervical cancer during pregnancy.
     Gynecol Oncol, 105(1): 269-72. [Abstract] [Full-text]
150. Nanoparticulate delivery system for insulin: design, characterization and in vitro/in vivo bioactivity.
     Eur J Pharm Sci, 30(5): 392-7. [Abstract] [Full-text]
151. Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8).
     Qual Life Res, 16(4): 577-91. [Abstract] [Full-text]
152. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
     Gynecol Oncol, 105(1): 211-7. [Abstract] [Full-text]
153. A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.
     Gynecol Oncol, 105(1): 223-7. [Abstract] [Full-text]
154. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.
     Eur Urol, 51(5): 1252-8. [Abstract] [Full-text]
155. Non-invasive optical biosensor for assaying endogenous G protein-coupled receptors in adherent cells.
     J Pharmacol Toxicol Methods, 55(3): 314-22. [Abstract] [Full-text]
156. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells.
     Gynecol Oncol, 105(1): 104-12. [Abstract] [Full-text]
157. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
     Gynecol Oncol, 105(1): 132-7. [Abstract] [Full-text]
158. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.
     Gynecol Oncol, 105(1): 59-65. [Abstract] [Full-text]
159. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
     Breast Cancer Res Treat, 102(3): 301-12. [Abstract] [Full-text]
160. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer.
     Breast Cancer Res Treat, 102(3): 375-81. [Abstract] [Full-text]
161. Evaluation of drug utilization and prescribing errors in infants: a primary care prescription-based study.
     Health Policy, 81(2): 350-7. [Abstract] [Full-text]
162. Anatomical and visual outcome of retinal angiomatous proliferation treated with photodynamic therapy and intravitreal triamcinolone.
     Am J Ophthalmol, 143(4): 701-4. [Abstract] [Full-text]
163. The reactive metabolite target protein database (TPDB)--a web-accessible resource.
     BMC Bioinformatics, 8: 95. [Abstract] [Full-text]
164. High-throughput determination of OROS drug release rate profile using micro parallel liquid chromatography.
     J Pharm Biomed Anal, 43(5): 1654-9. [Abstract] [Full-text]
165. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
     Biochem Pharmacol, 73(9): 1308-17. [Abstract] [Full-text]
166. On-chip generation of microbubbles as a practical technology for manufacturing contrast agents for ultrasonic imaging.
     Lab Chip, 7(4): 463-8. [Abstract] [Full-text]
167. Single-cell electroporation arrays with real-time monitoring and feedback control.
     Lab Chip, 7(4): 457-62. [Abstract] [Full-text]
168. Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration.
     Invest Ophthalmol Vis Sci, 48(4): 1767-72. [Abstract] [Full-text]
169. Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years.
     Eur J Endocrinol, 156(4): 425-30. [Abstract] [Full-text]
170. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke.
     Neurology, 68(13): 1020-4. [Abstract] [Full-text]
171. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
     Arch Intern Med, 167(6): 597-605. [Abstract] [Full-text]
172. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.
     Eur J Neurol, 14(4): 391-8. [Abstract] [Full-text]
173. Antimicrobial activity of cefazolin-impregnated mesh grafts.
     ANZ J Surg, 77(4): 256-60. [Abstract] [Full-text]
174. Can serum inflammatory parameters estimate outcome of pleurodesis in mesothelioma?
     ANZ J Surg, 77(4): 253-5. [Abstract] [Full-text]
175. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601.
     ANZ J Surg, 77(4): 247-52. [Abstract] [Full-text]
176. Recanalization and outcome after intra-arterial thrombolysis in middle cerebral artery and internal carotid artery occlusion: does sex matter?
     Stroke, 38(4): 1281-5. [Abstract] [Full-text]
177. Novel protein transduction method by using 11R: an effective new drug delivery system for the treatment of cerebrovascular diseases.
     Stroke, 38(4): 1354-61. [Abstract] [Full-text]
178. How diagnosis-related group 559 will change the US Medicare cost reimbursement ratio for stroke centers.
     Stroke, 38(4): 1309-12. [Abstract] [Full-text]
179. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
     Cancer, 109(7): 1384-90. [Abstract] [Full-text]
180. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
     Cancer, 109(7): 1255-63. [Abstract] [Full-text]
181. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
     Cancer, 109(7): 1413-9. [Abstract] [Full-text]
182. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia.
     Cancer, 109(7): 1376-83. [Abstract] [Full-text]
183. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
     Cancer, 109(7): 1355-9. [Abstract] [Full-text]
184. Endovascular recanalization of basilar artery occlusion 80 days after symptom onset.
     Stroke, 38(4): 1387-9. [Abstract] [Full-text]
185. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.
     Cancer, 109(7): 1303-11. [Abstract] [Full-text]
186. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.
     Ann Oncol, 18(4): 679-88. [Abstract] [Full-text]
187. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.
     Ann Oncol, 18(4): 694-700. [Abstract] [Full-text]
188. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
     Ann Oncol, 18(4): 730-7. [Abstract] [Full-text]
189. Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases.
     Ann Oncol, 18(4): 647-51. [Abstract] [Full-text]
190. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
     Ann Oncol, 18(4): 782-8. [Abstract] [Full-text]
191. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
     Ann Oncol, 18(4): 738-44. [Abstract] [Full-text]
192. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study.
     Ann Oncol, 18(4): 665-71. [Abstract] [Full-text]
193. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004.
     Diabetes Care, 30(4): 848-53. [Abstract] [Full-text]
194. Diabetic retinopathy and coronary implantation of sirolimus-eluting stents.
     J Interv Cardiol, 20(2): 122-31. [Abstract] [Full-text]
195. Drug-eluting stents versus bare metal stents following rotational atherectomy for heavily calcified coronary lesions: late angiographic and clinical follow-up results.
     J Interv Cardiol, 20(2): 100-6. [Abstract] [Full-text]
196. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
     Onkologie, 30(4): 169-74. [Abstract] [Full-text]
197. Challenges in the design and conduct of therapeutic trials in channel disorders.
     Neurotherapeutics, 4(2): 199-204. [Abstract] [Full-text]
198. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study.
     J Am Coll Cardiol, 49(12): 1283-8. [Abstract] [Full-text]
199. Hormone therapy is associated with smaller Achilles tendon diameter in active post-menopausal women.
     Scand J Med Sci Sports, 17(2): 128-32. [Abstract] [Full-text]
200. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers.
     Nat Rev Drug Discov, 6(4): 287-93. [Abstract] [Full-text]
201. Duty cycle dependence of ultrasound enhanced thrombolysis in a human clot model.
     Ultrasound Med Biol, 33(4): 576-83. [Abstract] [Full-text]
202. Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China.
     Prog Neuropsychopharmacol Biol Psychiatry, 31(3): 756-60. [Abstract] [Full-text]
203. Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy.
     Int J Radiat Oncol Biol Phys, 67(5): 1394-400. [Abstract] [Full-text]
204. Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
     Int J Radiat Oncol Biol Phys, 67(5): 1342-51. [Abstract] [Full-text]
205. A novel method for oral delivery of drug compounds to the neonatal SMNDelta7 mouse model of spinal muscular atrophy.
     J Neurosci Methods, 161(2): 285-90. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.